Abstract

AdaptHealth Corp. will report its second-quarter 2026 results on August 4, 2026, Pre-Market; investors are watching for revenue of roughly mid-single-digit year-over-year growth and an earnings inflection as cost headwinds from Q1 normalize.

Market Forecast

Consensus tracking points to a steady quarter: AdaptHealth Corp.’s current-quarter projections indicate revenue of 848.63 million US dollars, up 5.58% year over year, with EPS estimated at 0.17, up 47.83% year over year; EBIT is projected at 52.47 million US dollars, implying a 1.79% year-over-year decline. Gross profit margin and net margin forecasts were not disclosed, so the market’s headline focus is the revenue and EPS cadence alongside the EBIT bridge.

Main business momentum remains anchored in sleep therapy equipment, respiratory products, and home-based care solutions, with management previously highlighting companywide organic revenue growth of 9.10% year over year and signaling that labor costs tied to a new capitated partner implementation should normalize by the second quarter. The most promising near-term revenue and earnings lever is the scaled rollout of capitated payer partnerships that support patient onboarding and resupply, led by sleep therapy equipment (358.50 million US dollars last quarter), with the company citing growth across all reportable segments within the 9.10% organic uplift.

Last Quarter Review

In the prior quarter, AdaptHealth Corp. delivered revenue of 819.80 million US dollars, a gross profit margin of 16.21%, a GAAP net loss attributable to the company of 16.04 million US dollars (net margin -1.96%), and adjusted EPS of -0.12, down 140.00% year over year.

A key development was the temporary pressure from elevated labor costs tied to the rapid expansion to serve a new strategic partner; management indicated these costs would largely normalize by the second quarter, setting up a cleaner margin comparison. By business mix, sleep therapy equipment generated 358.50 million US dollars, respiratory products 178.14 million US dollars, diabetes 142.17 million US dollars, and home health 141.00 million US dollars; management noted growth across all reportable segments as part of 9.10% companywide organic growth year over year.

Current Quarter Outlook (with major analytical insights)

Core revenue engines: sleep therapy equipment and respiratory care

Sleep therapy equipment remains the largest revenue contributor, and its scale makes it central to how the quarter is likely to print on both revenue and margin. With revenue of 358.50 million US dollars last quarter and management describing broad-based organic growth, we expect volumes in sleep therapy and associated resupply programs to remain resilient on a year-over-year basis, consistent with the 5.58% company-level revenue growth outlook. The EBIT forecast showing a 1.79% year-over-year decline highlights the importance of the margin bridge: if labor and onboarding inefficiencies seen in Q1 subside as management suggested, the gross-to-EBIT conversion in core sleep therapy and respiratory categories should improve sequentially. These categories are also the most directly levered to the cadence of patient onboarding under payer agreements. In Q1, onboarding at pace created temporary duplication in regional staffing and elevated variable labor, but management flagged normalization by the end of Q2, which should support a cleaner expense run-rate and more indicative margin in these lines. If revenue trends track the 848.63 million US dollars estimate, the market will judge the quarter on whether sleep therapy and respiratory volumes translate to a stable or improving gross margin mix against Q1’s 16.21% baseline.

Most promising growth driver: capitated contracts and scaled onboarding

The new capitated contract and its broader application across geographies underpin the most material near-term growth optionality. Commentary following Q1 emphasized that higher labor spending facilitated a “smooth” go-live for the capitated model and positioned the company to extend the relationship beyond the initial term, signaling attractive lifetime value if unit economics meet expectations. For Q2, the key watch-points are pace of patient adds, resupply adherence, and any update on payout structures or quality metrics that affect the revenue recognition profile under capitated arrangements. Because this program touches multiple product categories, it can drive a blended revenue uplift while the expense profile normalizes. Execution matters: onboarding velocity must be matched with efficient scheduling and claims handling so that service intensity and support hours subside to steady-state levels. If those dynamics materialize, the EPS estimate of 0.17 (up 47.83% year over year) becomes more attainable even with a modest year-over-year EBIT decline, since the Q1 comparison included outsized implementation costs that should ease. The company previously raised full-year 2026 net revenue guidance to a range between 3.45 billion and 3.52 billion US dollars while maintaining adjusted EBITDA and free cash flow guidance ranges, which frames the runway this commercial model is expected to provide over the year.

Key stock-price drivers this quarter

Earnings per share and the margin trajectory will likely be the primary stock drivers around the print: delivery of the 0.17 EPS estimate alongside revenue near 848.63 million US dollars would support the notion that Q1’s expense spike was transient. Investors will scrutinize the gross-to-EBIT bridge, seeking clear evidence that variable labor and duplicative onboarding costs rolled off by the end of the quarter as guided. Any qualitative or quantitative update on payer partnerships—such as retention, per-patient revenue, or reduced friction in claims and documentation—could be a positive catalyst for the multiple. Recent developments add context to the quarter. The company disclosed a cybersecurity incident in early July and stated there was no material impact on operations or patient services; investors will look for additional color on remediation progress, costs, and whether cybersecurity insurance offsets any potential expense. Separately, an announced agreement for Cardinal Health to acquire AdaptHealth’s Diabetes Health business may reshape the revenue mix over time; while the timing suggests limited Q2 impact, management’s remarks on proceeds, use of cash, and margins for the continuing operations could influence forward estimates and valuation frameworks. Net-net, the immediate drivers are whether revenue growth converts to EPS in line with estimates and whether management can credibly point to a normalized expense base exiting the quarter.

Analyst Opinions

Bullish opinions dominate, representing roughly 75% of published recommendations in our review window, with no bearish calls observed and the remaining views characterized as neutral or hold. RBC Capital reiterated a Buy rating (analyst Ben Hendrix) and highlighted that incremental labor spending in Q1 expedited the onboarding of a major capitated contract, improving the odds of extending the relationship beyond its initial five-year period; RBC has discussed price targets in the low-to-mid teens, emphasizing the contract’s proof-of-concept and the path to operational right-sizing as variable labor normalizes by the end of Q2. UBS also maintained a Buy rating while modestly trimming its target from 15 to 14 US dollars, indicating continued confidence in the multi-quarter recovery arc even as near-term profitability absorbs the tail end of the onboarding investment. The through-line across supportive research is consistent: the top-line appears stable in the mid-single digits, and the key determinant of upside is the expense normalization that allows the revenue base—particularly in sleep therapy and related categories—to translate more efficiently into EBIT and EPS. Analysts point to the company’s updated 2026 net revenue outlook, maintained adjusted EBITDA and free cash flow guidance ranges, and the anticipated benefits from capitated programs as evidence that the Q1 reset was tactical rather than structural. In this context, the 0.17 EPS estimate (up 47.83% year over year) is framed as achievable if the cost roll-off is visible and if Q2 commentary confirms healthy patient adds, resupply adherence, and tighter operational workflows. Bullish research also flags secondary potential positives. The cybersecurity incident, while serious, has been described by the company as contained with no material impact on operations or patient services; analysts appear to view follow-through actions and transparency as important but not thesis-breaking. Additionally, portfolio moves such as the announced sale of the Diabetes Health business could streamline the operating model and, depending on proceeds and deployment, enhance the balance sheet or fund higher-return initiatives in core categories; near-term, analysts will parse management’s capital allocation priorities and any implications for margin mix. Overall, the majority view anticipates Q2 results that are directionally in line with revenue estimates and confirm an inflection in profitability metrics versus Q1’s onboarding dynamic, which would support a higher-quality earnings base into the second half of 2026.